Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Business Wire
– Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter –– Successful completion of end-of-phase 2 FDA meeting for pain associated with diabetic peripheral neuropathy (DPN); Phase 3 program to initiate in 2H 2024 –– Breakthrough Therapy designation for pain associated with DPN granted by FDA –– Enrollment of Phase 2 study in patients with painful lumbosacral radiculopathy on track to complete by end of year – BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548).Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has g
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Disease (AMKD) Awareness Day [Yahoo! Finance]Yahoo! Finance
- Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- 2 Top Growth Stocks to Buy Right Now and Hold Forever [Yahoo! Finance]Yahoo! Finance
- Pioneer Institute study finds IRA discourages non-opioid drug innovation [Yahoo! Finance]Yahoo! Finance
- Vertex Announces European Commission Approval for KALYDECO® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/17/24 - Form 4
- 4/16/24 - Form PX14A6G
- 4/11/24 - Form SC
- VRTX's page on the SEC website